key: cord-1028454-quw5ufik
authors: Götzinger, Florian; Santiago-Garcia, Begoña; Fumadó-Pérez, Victòria; Brinkmann, Folke; Tebruegge, Marc
title: The ability of the neonatal immune response to handle SARS-CoV-2 infection
date: 2021-01-21
journal: Lancet Child Adolesc Health
DOI: 10.1016/s2352-4642(21)00002-x
sha: da265abb57d7e89b29bf1e6a2cc5a1b47b0976f3
doc_id: 1028454
cord_uid: quw5ufik

nan

We read with interest the Article by Chris Gale and colleagues reporting data from active surveillance of neonatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the first COVID-19 wave in the UK. 1 The authors are to be commended for the detailed presentation of their data, and the overall carefully worded interpretation.

However, the authors appear to contradict themselves in the Discussion section, initially stating that "neonatal SARS-CoV-2 infection led to severe disease in 42% of cases" and highlighting that 33% of babies required respiratory support. Contrasting with this, in the final paragraph the authors state that "most babies are only mildly affected in the neonatal period."

We have previously published data from a multicentre study on SARS-CoV-2 infection, involving 82 health-care institutions in 25 European countries, which included 582 children with PCR-confirmed SARS-CoV-2 infection. 2 Prompted by the Article by Gale and colleagues, we did secondary data analyses that were focused on neonatal cases (aged <28 days) in our cohort.

Our study population included 35 neonates, four (11%) of whom required mechanical ventilation (table), compared with 21 (4%) of 547 children older than 1 month (two-sided Fisher's exact test, p=0·0561). However, three of these neonates had substantial comorbidities, comprising cardiac anomalies (n=2) and prematurity (n=1), which might have caused the need for ventilatory support, rather than SARS-CoV-2. Considering this uncertainty, if the analysis is repeated with the only patient who required mechanical ventilation for SARS-CoV-2 infection alone, the proportion of neonates requiring ventilation would be similar to that observed in older children without pre-existing comorbidities in our cohort (one [3%] of 32 vs six [2%] of 299; p=0·5059]. An additional three neonates needed supplemental oxygen without requiring ventilation (one born prematurely); none of these neonates had evidence of acute respiratory distress syndrome on chest radiography. Only three of those seven neonates received medication aimed at treating SARS-CoV-2 infection. One baby received intravenous immunoglobulin; another hydroxychloroquine, which was a promising drug candidate at that time, but subsequently found to be ineffective; 3 and one received remdesivir on a compassionate basis.

The large majority (80%) of neonates did not require respiratory support at any stage, and almost one in five remained entirely asymptomatic (table) . Importantly, all 35 neonates survived, and none had evidence of COVID-19-related sequelae at discharge.

Our data indicate that the neonatal immune system, despite its inherent immaturity, 4,5 is able to handle SARS-CoV-2 effectively, with most infected neonates either being asymptomatic or experiencing mild disease, which is concordant with the findings of two meta-analyses. 6, 7 We declare no competing interests No respiratory support required 28 (80%)

ARDS=acute respiratory distress syndrome. NICU=neonatal intensive care unit. PICU=paediatric intensive care unit. *Comorbidities comprised prematurity (born <37 weeks of gestation; n=3); cardiac anomalies (n=3); gastro-oesophageal reflux disease (n=1); urogenital malformation (n=1); and red cell disorder (n=1). †Some neonates had more than one symptom. ‡Only 12 neonates had a chest radiograph. §Some neonates received more than one type of respiratory support. FG and MT conducted the secondary data analyses reported in this manuscript, and wrote the first draft. BS-G, VF-P, and FB interpreted the data, and reviewed and revised the manuscript. The remaining members of the ptbnet COVID-19 Study Group (appendix) also reviewed the manuscript, provided additional input, and approved the manuscript to be submitted for publication. The corresponding author had full access to all data and the final responsibility to submit for publication. 

Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19

Protecting the newborn and young infant from infectious diseases: lessons from immune ontogeny

Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections

Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis

Synthesis and systematic review of reported neonatal SARS-CoV-2 infections